Exhibit 99.2
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION
Introduction
On September 29, 2025, Barinthus Biotherapeutics plc, a public limited company organized under the laws of England and Wales (“Barinthus Bio”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among Barinthus Bio, Clywedog Therapeutics Holdings, Inc. (formerly known as Beacon Topco, Inc.), a Delaware corporation and a direct wholly owned subsidiary of Barinthus Bio (“Topco”), Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco (“Merger Sub”), and Clywedog Therapeutics, Inc., a Delaware corporation (“Clywedog”).
The Merger Agreement provides that, among other things, upon the terms and subject to the conditions set forth therein (i) Topco will acquire the entire issued and to be issued share capital of Barinthus Bio pursuant to a scheme of arrangement (subject to any modification, addition or condition which (a) Barinthus Bio, Topco and Clywedog mutually agree and which (if required) is approved by the High Court of Justice of England and Wales (the “Court”) or (b) is otherwise imposed by the Court and mutually acceptable to Barinthus Bio, Topco and Clywedog, each acting reasonably and in good faith, in each case in accordance with Part 26 of the United Kingdom Companies Act 2006 and the Merger Agreement (the “Scheme of Arrangement” and such transaction, the “Scheme Transaction”)), resulting in Barinthus Bio becoming a direct wholly owned subsidiary of Topco, and (ii) Merger Sub will merge with and into Clywedog, with Clywedog continuing as the surviving corporation and a direct wholly owned subsidiary of Topco in accordance with the Delaware General Corporation Law (the “Merger” and together with the Scheme Transaction, the “Combinations”, and, together with such other transactions contemplated by the Merger Agreement, the “Contemplated Transactions”). The Scheme Transaction was consummated on September 9, 2026 and the Merger was consummated on November 20, 2026.
At the effective time of the Scheme Transaction (the “Scheme Effective Time”), upon the terms and subject to the conditions set forth in the Merger Agreement, Topco acquired each outstanding ordinary share of Barinthus Bio, with a par value of £0.000025 per ordinary share (each such acquired ordinary share, a “Scheme Share”), which, for the avoidance of doubt, will include ordinary shares held by The Bank of New York Mellon (the “Depositary”) (or to the extent that the Depositary is not itself the registered holder of such shares that underlie Barinthus Bio’s American Depositary Shares (the “ADSs”), each representing one (1) ordinary share, whichever nominee, custodian or other entity is the registered holder under the terms of the Deposit Agreement, dated as of April 29, 2021, among Barinthus Bio, the Depositary, and all holders from time to time of the ADSs, as may be amended from time to time), from the holders of Scheme Shares whose names appear in the register of members of Barinthus Bio at the Scheme Effective Time) in accordance with the provisions of the Scheme of Arrangement, and each Scheme Share was converted into the right to receive (i) 0.111 shares of common stock, $0.0001 par value per share, of Topco (the “Topco Common Stock”), rounded down to the nearest whole share plus (ii) cash in lieu of any fractional shares.
On October 19, 2026, Topco completed a self-tender offer in which Topco accepted for purchase 920,605 shares of its common stock, par value $0.0001 per share that were properly tendered at a price of $6.6609 per share, for an aggregate purchase price of approximately $6.1 million (the “Self-Tender Offer”).
On November 20, 2026 (the “Merger Effective Time”), subject to adjustment in accordance with the terms of the Merger Agreement, each share of common stock, $0.0001 par value per share, of Clywedog (the “Clywedog Common Stock”) and each share of Series Seed Preferred Stock, $0.0001 par value per share, of Clywedog (the “Clywedog Preferred Stock”, and together with the Clywedog Common Stock, the “Clywedog Shares”), other than Clywedog Shares held as treasury stock or owned by Topco or Merger Sub immediately prior to the Merger Effective Time, was converted solely into the right to receive (i) 0.741416 shares of Topco Common Stock, rounded down to the nearest whole share plus (ii) cash in lieu of any fractional shares.
| 1 |
Immediately following completion of the Combinations, former Clywedog stockholders owned approximately 66% of Topco on a fully diluted basis and former Barinthus Bio Shareholders owned approximately 34% of Topco on a fully diluted basis, based on the respective capitalizations of Clywedog and Barinthus Bio as of the date the parties entered into the Merger Agreement.
The following unaudited pro forma condensed combined financial information has been prepared in accordance with Article 11 of Regulation S-X, as amended, and presents the combination of the historical financial information of Barinthus Bio and Clywedog adjusted to give effect to the Merger and the other events contemplated by the Merger Agreement, including the Self-Tender Offer.
The unaudited pro forma condensed combined balance sheet as of June 30, 2026 combines the historical unaudited condensed consolidated balance sheet of Barinthus Bio and the historical unaudited condensed consolidated balance sheet of Clywedog on a pro forma basis as if the Contemplated Transactions had been consummated on June 30, 2026.
The unaudited pro forma condensed combined statement of operations and comprehensive loss for the six months ended June 30, 2026 combines the historical unaudited condensed consolidated statement of operations and comprehensive loss of Barinthus Bio for the six months ended June 30, 2026 and the historical unaudited condensed consolidated statement of operations of Clywedog for the six months ended June 30, 2026. The unaudited pro forma condensed combined statement of operations and comprehensive loss for the year ended December 31, 2025 combines the historical audited consolidated statement of operations and comprehensive loss of Barinthus Bio for the year ended December 31, 2025 and the historical audited consolidated statement of operations of Clywedog for the year ended December 31, 2025. The unaudited pro forma condensed combined statement of operations and comprehensive loss for the six months ended June 30, 2026 and for the year ended December 31, 2025 are presented on a pro forma basis as if the Contemplated Transactions had been consummated on January 1, 2025, the beginning of the earliest period presented.
The transaction accounting adjustments include adjustments related to the recognition of the following items:
| · | The Self-Tender Offer; | |
| · | Transaction costs relating to the Contemplated Transactions; | |
| · | Conversion of Clywedog’s SAFE notes and Redeemable convertible preferred stock into Topco common stock; | |
| · | The elimination of pre-acquisition equity of Barinthus Bio, the accounting acquiree; | |
| · | The par value of Topco common stock after the Contemplated Transactions; | |
| · | Adjustments relating to share-based compensation expense in connection with the replacement of Barinthus Options with Topco stock options; and | |
| · | Recognition of a gain on bargain purchase. |
| 2 |
The unaudited pro forma condensed combined financial information has been presented for illustrative purposes only and is not necessarily indicative of the financial position and results of operations that would have been achieved had the Contemplated Transactions occurred on the dates indicated. Further, the unaudited pro forma condensed combined financial information may not be useful in predicting the future financial condition and results of operations of the combined company. The actual financial position and results of operations may differ significantly from the pro forma amounts reflected herein due to a variety of factors. The unaudited pro forma adjustments represent management’s estimates based on information available as of the date of the unaudited pro forma condensed combined financial information and is subject to change as additional information becomes available and analyses are performed. This information should be read together with the following:
| · | The accompanying Notes to the unaudited pro forma condensed combined financial information; | |
| · | The historical unaudited condensed consolidated financial statements of Barinthus Bio as of and for the six months ended June 30, 2026; | |
| · | The historical audited consolidated financial statements of Barinthus Bio as of and for the year ended December 31, 2025; | |
| · | The historical unaudited condensed consolidated financial statements of Clywedog as of and for the six months ended June 30, 2026; and | |
| · | The historical audited consolidated financial statements of Clywedog as of and for the year ended December 31, 2025. |
Accounting Treatment
The Combinations will be accounted for as a business combination in accordance with U.S. GAAP (pursuant to Accounting Standards Codification Topic 805, Business Combinations (“ASC 805”)), with Clywedog treated as the “accounting acquirer” and Barinthus Bio treated as the “legal acquirer” for financial reporting purposes. The Combinations meet the definition of a business combination because Barinthus Bio meets the definition of a business, with inputs in the form of its in-process research and development and operating facilities; and substantive processes in the form of its assembled workforce. Clywedog will control Barinthus Bio as it will beneficially own a majority voting interest of the outstanding shares of Topco Common Stock after completion of the Combinations. The unaudited pro forma condensed combined financial information was prepared using the acquisition method of accounting. Under the acquisition method of accounting, the purchase price is allocated to the identifiable tangible and intangible assets acquired and liabilities assumed of Barinthus Bio based on their respective estimated fair values with any excess purchase price allocated to goodwill. Where the fair value of the identifiable tangible and intangible assets acquired and liabilities assumed exceeds the fair value of the purchase consideration transferred, the excess is recorded as a gain on bargain purchase. Significant estimates and assumptions were used in determining the preliminary purchase price and the preliminary purchase price allocation reflected in the unaudited pro forma condensed combined financial information. The process of valuing the net assets of pre-combination Barinthus Bio immediately prior to the business combination for purposes of presentation within this unaudited pro forma condensed combined financial information is preliminary. As the unaudited pro forma condensed combined financial information has been prepared based on these preliminary estimates, the final amounts recorded may differ materially from the information presented.
Clywedog was determined to be the accounting acquirer based on evaluation of the following facts and circumstances:
| · | Clywedog existing stockholders have the greatest voting interest in the post-combination company; | |
| · | Clywedog existing operations comprise the majority of ongoing clinical operations of the post-combination company; and | |
| · | Clywedog existing stockholders can elect the majority of the post-combination company board of directors. |
| 3 |
Clywedog Therapeutics Holdings, Inc.
Unaudited Pro Forma Condensed Combined Balance Sheet
As of June 30, 2026
(in thousands, except number of shares and per share amounts)
| (1) Clywedog (Historical) | (2) Barinthus Bio (Historical) | Transaction Accounting Adjustments | Pro Forma Combined | |||||||||||||
| ASSETS | ||||||||||||||||
| Cash and cash equivalents | $ | 69 | $ | 59,295 | $ | (6,132 | )(A) | $ | 42,024 | |||||||
| (11,208 | )(B) | |||||||||||||||
| Restricted cash | — | 335 | — | 335 | ||||||||||||
| Research and development incentives receivable | — | 1,281 | — | 1,281 | ||||||||||||
| Prepaid research and development - related party | 2,118 | — | 2,118 | |||||||||||||
| Prepaid expenses and other current assets | 74 | 2,362 | — | 2,436 | ||||||||||||
| Total current assets | 2,261 | 63,273 | (17,340 | ) | 48,194 | |||||||||||
| Property and equipment, net | — | 3,038 | — | 3,038 | ||||||||||||
| Intangible assets, net | — | 13,045 | (8,845 | )(E) | 4,200 | |||||||||||
| Right of use assets, net | — | 1,618 | — | 1,618 | ||||||||||||
| Prepaid research and development - related party, non-current | 146 | — | 146 | |||||||||||||
| Prepaid research and development, non-current | 512 | — | 512 | |||||||||||||
| Other assets | — | 919 | — | 919 | ||||||||||||
| Total assets | $ | 2,919 | $ | 81,893 | $ | (26,185 | ) | $ | 58,627 | |||||||
| LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ (DEFICIT) EQUITY | ||||||||||||||||
| Current liabilities: | ||||||||||||||||
| Accounts payable - related party | $ | 10,909 | $ | — | $ | — | $ | 10,909 | ||||||||
| Accounts payable | 4,279 | 535 | (1,063 | )(B) | 3,751 | |||||||||||
| Accrued research and development - related parties | 453 | — | — | 453 | ||||||||||||
| Accrued expenses and other current liabilities | 1,353 | 8,829 | (5,294 | )(B) | 4,888 | |||||||||||
| Notes payable - related parties | 1,540 | — | — | 1,540 | ||||||||||||
| Deferred income | — | 335 | — | 335 | ||||||||||||
| Operating lease liability – current | — | 1,724 | — | 1,724 | ||||||||||||
| Total current liabilities | 18,534 | 11,423 | (6,357 | ) | 23,600 | |||||||||||
| Non-current liabilities: | ||||||||||||||||
| SAFE liability – related parties | 20,663 | — | (20,663 | )(C) | — | |||||||||||
| Operating lease liability – non-current | — | 8,571 | — | 8,571 | ||||||||||||
| Contingent consideration | — | 3,063 | — | 3,063 | ||||||||||||
| Other non-current liabilities | — | 1,487 | — | 1,487 | ||||||||||||
| Deferred tax liability, net | — | 215 | — | 215 | ||||||||||||
| Total liabilities | $ | 39,197 | $ | 24,759 | $ | (27,020 | ) | $ | 36,936 | |||||||
| Redeemable convertible preferred stock | 12,774 | — | (12,774 | )(D) | — | |||||||||||
| Stockholders’ (deficit) equity: | ||||||||||||||||
| Ordinary shares (Common stock) | — | 1 | 1 | (D) | 1 | |||||||||||
| (1 | )(E) | |||||||||||||||
| Deferred A shares | — | 86 | (86 | )(E) | — | |||||||||||
| Treasury Stock | — | — | (6,132 | )(A) | — | |||||||||||
| 6,132 | (E) | |||||||||||||||
| Additional paid-in capital | — | 394,932 | (3,285 | )(B) | 58,734 | |||||||||||
| 20,663 | (C) | |||||||||||||||
| 12,773 | (D) | |||||||||||||||
| (366,349 | )(E) | |||||||||||||||
| Accumulated deficit | (49,052 | ) | (320,208 | ) | (1,566 | )(B) | (37,105 | ) | ||||||||
| 333,721 | (E) | |||||||||||||||
| Accumulated other comprehensive loss – foreign currency translation adjustments | — | (17,738 | ) | 17,738 | (E) | — | ||||||||||
| Total stockholders’ (deficit) equity attributable to Clywedog Therapeutics Holdings, Inc. shareholders | (49,052 | ) | 57,073 | 13,609 | 21,630 | |||||||||||
| Noncontrolling interest | — | 61 | — | 61 | ||||||||||||
| Total stockholders’ (deficit) equity | $ | (49,052 | ) | $ | 57,134 | $ | 13,609 | $ | 21,691 | |||||||
| Total liabilities, redeemable convertible preferred stock and stockholders’ (deficit) equity | $ | 2,919 | $ | 81,893 | $ | (26,185 | ) | $ | 58,627 | |||||||
| 4 |
Clywedog Therapeutics Holdings, Inc.
Unaudited Pro Forma Condensed Combined Statement of Operations and
Comprehensive Loss
For the Six Months Ended June 30, 2026
(in thousands, except share and per share amounts)
| (5) Clywedog (Historical) |
(6) Barinthus Bio (Historical) |
Transaction Accounting Adjustments |
Pro Forma Combined |
|||||||||||||
| Operating expenses | ||||||||||||||||
| Research and development | $ | 6,060 | $ | 7,516 | $ | 5 | (DD) | $ | 13,581 | |||||||
| Research and development-related parties | 5,686 | — | — | 5,686 | ||||||||||||
| General and administrative | 873 | 9,629 | (6,664 | )(AA) | 3,855 | |||||||||||
| 17 | (DD) | |||||||||||||||
| Total operating expenses | 12,619 | 17,145 | (6,642 | ) | 23,122 | |||||||||||
| Other operating income | — | 51 | — | 51 | ||||||||||||
| Loss from operations | (12,619 | ) | (17,094 | ) | 6,642 | (23,071 | ) | |||||||||
| Other income/(expense): | ||||||||||||||||
| Interest income | — | 693 | — | 693 | ||||||||||||
| Interest expense | — | (27 | ) | — | (27 | ) | ||||||||||
| Interest expense – related parties | (63 | ) | — | — | (63 | ) | ||||||||||
| Loss on change in fair value of SAFE instruments - related parties | (314 | ) | — | 314 | (BB) | — | ||||||||||
| Research and development incentives | — | 191 | — | 191 | ||||||||||||
| Other income | — | 65 | — | 65 | ||||||||||||
| Total other income, net | (377 | ) | 922 | 314 | 859 | |||||||||||
| Loss before income tax | (12,996 | ) | (16,172 | ) | 6,956 | (22,212 | ) | |||||||||
| Tax benefit | — | 39 | — | 39 | ||||||||||||
| Net loss | (12,996 | ) | (16,133 | ) | 6,956 | (22,173 | ) | |||||||||
| Net loss attributable to noncontrolling interest | — | 22 | — | 22 | ||||||||||||
| Net loss attributable to shareholders | (12,996 | ) | (16,111 | ) | 6,956 | (22,151 | ) | |||||||||
| Weighted-average common shares outstanding, basic and diluted | 1,512,000 | 40,848,893 | (31,834,759 | )(EE) | 10,526,134 | |||||||||||
| Net loss per share attributable to common shareholders, basic and diluted | $ | (8.60 | ) | $ | (0.39 | ) | $ | (2.10 | ) | |||||||
| Net loss | $ | (12,996 | ) | $ | (16,133 | ) | $ | 6,956 | $ | (22,173 | ) | |||||
| Other comprehensive (loss) gain – foreign currency translation adjustments | — | (2,014 | ) | — | (2,014 | ) | ||||||||||
| Comprehensive loss | (12,996 | ) | (18,147 | ) | 6,956 | (24,187 | ) | |||||||||
| Comprehensive loss attributable to noncontrolling interest | — | 23 | — | 23 | ||||||||||||
| Comprehensive loss attributable to shareholders | $ | (12,996 | ) | $ | (18,124 | ) | $ | 6,956 | $ | (24,164 | ) | |||||
| 5 |
Clywedog Therapeutics Holdings, Inc.
Unaudited Pro Forma Condensed Combined Statement of Operations and
Comprehensive Loss
For the Year Ended December 31, 2025
(in thousands, except share and per share amounts)
| (3) Clywedog (Historical) |
(4) Barinthus Bio (Historical) |
Transaction Accounting Adjustments |
Pro Forma Combined |
|||||||||||||
| Operating expenses | ||||||||||||||||
| Research and development | $ | 3,948 | $ | 25,564 | $ | 27 | (DD) | $ | 29,539 | |||||||
| Research and development-related parties | 9,242 | — | — | 9,242 | ||||||||||||
| General and administrative | 1,644 | 40,830 | 2,743 | (AA) | 45,303 | |||||||||||
| 86 | (DD) | |||||||||||||||
| Impairment of Intangible assets | — | 4,667 | — | 4,667 | ||||||||||||
| Total operating expenses | 14,834 | 71,061 | 2,856 | 88,751 | ||||||||||||
| Other operating income | — | 506 | — | 506 | ||||||||||||
| Loss from operations | (14,834 | ) | (70,555 | ) | (2,856 | ) | (88,245 | ) | ||||||||
| Other income/(expense): | ||||||||||||||||
| Gain on extinguishment of debt – related party | 1,365 | — | — | 1,365 | ||||||||||||
| Interest income | — | 1,957 | — | 1,957 | ||||||||||||
| Interest expense | — | (51 | ) | — | (51 | ) | ||||||||||
| Interest expense– related parties | (131 | ) | — | — | (131 | ) | ||||||||||
| Loss on change in fair value of SAFE instruments - related parties | (3,405 | ) | — | 3,405 | (BB) | — | ||||||||||
| Research and development incentives | — | 2,000 | — | 2,000 | ||||||||||||
| Other income | — | 16 | — | 16 | ||||||||||||
| Gain on bargain purchase | — | — | 13,513 | (CC) | 13,513 | |||||||||||
| Total other income, net | (2,171 | ) | 3,922 | 16,918 | 18,669 | |||||||||||
| Loss before income tax | (17,005 | ) | (66,633 | ) | 14,061 | (69,577 | ) | |||||||||
| Tax benefit | — | 175 | — | 175 | ||||||||||||
| Net loss | (17,005 | ) | (66,458 | ) | 14,061 | (69,402 | ) | |||||||||
| Net loss attributable to noncontrolling interest | — | 30 | — | 30 | ||||||||||||
| Net loss attributable to shareholders | (17,005 | ) | (66,428 | ) | 14,061 | (69,372 | ) | |||||||||
| Weighted-average common shares outstanding, basic and diluted | 1,512,000 | 40,527,218 | (31,513,084 | )(EE) | 10,526,134 | |||||||||||
| Net loss per share attributable to common shareholders, basic and diluted | $ | (11.25 | ) | $ | (1.64 | ) | $ | (6.59 | ) | |||||||
| Net loss | $ | (17,005 | ) | $ | (66,458 | ) | $ | 14,061 | $ | (69,402 | ) | |||||
| Other comprehensive (loss) gain – foreign currency translation adjustments | — | 10,145 | — | 10,145 | ||||||||||||
| Comprehensive loss | (17,005 | ) | (56,313 | ) | 14,061 | (59,257 | ) | |||||||||
| Comprehensive loss attributable to noncontrolling interest | — | 22 | — | 22 | ||||||||||||
| Comprehensive loss attributable to shareholders | $ | (17,005 | ) | $ | (56,291 | ) | $ | 14,061 | $ | (59,235 | ) | |||||
| 6 |
NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION
1. Basis of Presentation
The unaudited pro forma condensed combined financial information has been adjusted to give effect to transaction accounting adjustments related to the Combinations linking the effects of the Combinations and the Self-Tender Offer to the historical financial information.
The Combinations will be accounted for as a reverse merger under the acquisition method of accounting for business combinations pursuant to the provisions of ASC 805. As noted above, Clywedog has been determined to be the accounting acquirer. Under the acquisition method of accounting, the estimated purchase price will be allocated to Barinthus Bio’s assets acquired and liabilities assumed based upon their estimated fair values at the date of completion of the Merger. Any excess of the preliminary estimate of the fair value of identified assets acquired and liabilities assumed over the merger consideration will be recognized as a gain on bargain purchase. Significant judgment is required in determining the preliminary fair values of identified intangible assets, certain other assets, and other assumed liabilities and non-controlling interest. Additionally, the final purchase price allocation will depend on a number of factors that cannot be predicted with certainty at this time. The final valuation may materially change the purchase price and the allocation of the purchase price, which could materially affect the fair values assigned to the assets, liabilities and non-controlling interest and could result in a material change to the unaudited pro forma condensed combined financial information.
The following unaudited pro forma condensed combined financial information presents the combination of the financial information of Barinthus Bio and Clywedog adjusted to give effect to the Combinations and other events contemplated by the Merger Agreement. The unaudited pro forma condensed combined balance sheet as of June 30, 2026 combine the historical condensed consolidated balance sheets of Barinthus Bio and Clywedog on a pro forma basis assuming the business combination and related transactions had been consummated on June 30, 2026. The unaudited pro forma condensed combined statements of operations and comprehensive loss for the six months ended June 30, 2026 and for the year ended December 31, 2025 combine the historical statements of operations and comprehensive loss of Barinthus Bio and Clywedog on a pro forma basis assuming the business combination and related transactions had occurred on January 1, 2025, the beginning of the earliest period presented.
The unaudited pro forma condensed combined financial information is not necessarily indicative of what the actual results of operations and financial position would have been had the Combinations and related events taken place on the dates indicated, nor are they indicative of the future consolidated results of operations or financial position of Topco and they are based on the information available at the time of their preparation. Actual results may differ materially from the assumptions within the unaudited pro forma condensed combined financial information.
| 7 |
The pro forma adjustments are based on currently available information and assumptions that management believes are reasonable under the circumstances. Such adjustments are preliminary and may change as additional information becomes available and further analyses are completed.
2. Estimated Purchase Price
The preliminary estimated purchase price, which represents the consideration transferred to Barinthus Bio stockholders in this reverse acquisition, is calculated as follows: the share price of Topco shares repurchased in the Self-Tender Offer completed on October 19, 2026, multiplied by the number of Barinthus Bio Ordinary Shares and Deferred A Shares that were exchanged in connection with the Scheme (on a post-Scheme exchange basis) and reduced by the number of shares repurchased under the Self-Tender Offer.
The fair value of replacement stock options of $1.4 million is split between pre-combination service ($1.3 million, included in the Estimated Purchase Consideration) and post-combination service ($0.1 million, to be recognized as expense post-combination over remaining service period). These amounts are based on the fair value, as of September 9, 2026, of Topco’s stock options which are issued as a replacement for the Barinthus stock options.
The accompanying unaudited pro forma condensed combined financial information reflects the purchase price of $25.4 million which consists of the following:
| Number of Shares | ||||
| Barinthus Bio Ordinary and Deferred A shares exchanged in the Scheme into Topco shares | 4,534,227 | |||
| Less: shares repurchased under the Self-Tender Offer | (920,605 | ) | ||
| Barinthus Bio Ordinary and Deferred A shares after the Self-Tender Offer | 3,613,622 | |||
| Share price of Topco shares repurchased in the Self-Tender Offer on October 19, 2026 (1) | $ | 6.6609 | ||
| Amount (in thousands) |
||||
| Fair value of Barinthus Bio shares | $ | 24,070 | ||
| Fair value of replacement stock options | 1,289 | |||
| Total Estimated Purchase Consideration (1) | $ | 25,359 | ||
(1) The final purchase consideration will be computed using the opening trading price of shares of the combined company on The Nasdaq Stock Market after completion of the Merger, which is expected to be equal to $6.6609 as estimated above. This estimate could change which would result in a difference between the final purchase consideration and the estimate used in these unaudited pro forma condensed combined financial information.
3. Preliminary Purchase Price Allocation
The allocation of the estimated preliminary purchase price with respect to the Combinations is based upon management’s estimates of, and assumptions related to, the fair values of assets to be acquired and liabilities to be assumed as of June 30, 2026, using currently available information. Due to the fact that the unaudited pro forma condensed combined financial information has been prepared based on these preliminary estimates, the final purchase price allocation and the resulting effect on the combined company’s financial position and results of operations may differ materially from the pro forma amounts included herein.
The following table sets forth a preliminary allocation of the purchase consideration to the identifiable tangible and intangible assets acquired, liabilities assumed and the non-controlling interest as if the Combinations had occurred on June 30, 2026. The difference between the purchase consideration and the fair value of the identifiable net assets acquired is reflected as a gain on bargain purchase. The fair values of the assets acquired and liabilities assumed approximate the historical carrying values as of June 30, 2026, with the exception of (i) a decrease of $6.1 million in the carrying value of cash to reflect the Self-Tender Offer, (ii) an increase of $3.3 million in accrued expenses and other current liabilities for transaction costs of Barinthus incurred or expected to be incurred after June 30, 2026, and (iii) a decrease of $8.8 million in intangible assets to reflect estimated fair value.
| 8 |
| Amount (in thousands) |
||||
| Cash and cash equivalents | $ | 53,163 | ||
| Restricted cash | 335 | |||
| Research and development incentives receivable | 1,281 | |||
| Prepaid expenses and other current assets | 2,362 | |||
| Property and equipment, net(ii) | 3,038 | |||
| Intangible assets, net(i) | 4,200 | |||
| Right-of-use assets, net(iii) | 1,618 | |||
| Other assets | 919 | |||
| Total Assets Acquired | 66,916 | |||
| Accounts payable | 535 | |||
| Accrued expenses and other current liabilities | 12,114 | |||
| Deferred income(iv) | 335 | |||
| Operating lease liability – current | 1,724 | |||
| Operating lease liability – non-current | 8,571 | |||
| Contingent consideration | 3,063 | |||
| Other non-current liabilities | 1,487 | |||
| Deferred tax liability, net | 215 | |||
| Total Liabilities Assumed | 28,044 | |||
| Net Assets Acquired | $ | 38,872 | ||
| Total Estimated Purchase Consideration | $ | 25,359 | ||
| Gain on Bargain Purchase | $ | 13,513 | ||
The preliminary purchase price allocation is based on a preliminary assessment of the fair values of the assets acquired, liabilities assumed and non-controlling interest as of June 30, 2026. Management reassessed the acquisition accounting before recognizing the gain, including verifying the completeness of acquired assets and assumed liabilities. The estimated gain on bargain purchase presented in the table above is expected to change (decrease) when computed using the balances of net assets acquired as of a date closer to the completion of the Merger.
(i) A preliminary fair value estimate of $4.2 million has been assigned to in-process research and development (“IPR&D”) projects acquired. The preliminary fair value of IPR&D assets was determined primarily using the “income approach.” In assessing fair value, Clywedog considered a potential market participant’s assessment of the highest and best use of the asset including whether the value would be derived through commercialization or sale.
For the IPR&D assets valued using the income approach, which includes the programs under development, the methodology applied considers the fair value of an IPR&D asset by reference to the present value of the probability-weighted expected cash flows arising under certain sale, out-licensing or commercialization scenarios, with a discount rate selected to appropriately consider the time value of money and the risks inherent in those forecasts. The income approach is based on the premise that the value of an asset is the present value of the future earning capacity that is available for distribution to investors in that asset.
Acquired IPR&D assets are classified as indefinite lived assets until the successful completion or abandonment of the associated research and development efforts. Accordingly, during the development period after the closing date of the Merger, the IPR&D assets will not be amortized; instead they will be subject to periodic impairment testing. Upon successful completion of the development process for acquired IPR&D projects, determination as to the useful life of the specific asset will be made; at that point in time, the asset will then be considered a finite lived intangible asset and Clywedog will begin to amortize the asset into earnings.
| 9 |
These preliminary estimates of fair value of the IPR&D assets could potentially be different from those determined through the final acquisition accounting, and the difference could potentially have a material impact on the accompanying Unaudited Pro Forma Condensed Combined Financial Information. As Clywedog obtains additional information in respect of the Barinthus Bio intangible assets, additional insight could be gained which could impact (i) the estimated total value assigned to intangible assets, and/or (ii) the estimated allocation of value between finite lived and indefinite lived intangible assets. The estimated intangible asset fair values and their useful lives could be impacted by a variety of factors that may become known to us only upon access to additional information and/or by changes in such factors that may occur prior to the effective time of the Merger. These factors include but are not limited to the regulatory, legislative, legal, technological and competitive environments. Increased knowledge about these and/or other elements could result in a change to the estimated fair value of Barinthus Bio’s intangible assets and/or to the estimated weighted average useful lives from that assumed by Clywedog in these Unaudited Pro Forma Condensed Combined Financial Information.
(ii) A preliminary fair value estimate of $3.0 million has been assigned to property, plant and equipment to be acquired, primarily consisting of computer and lab equipment and furniture and fixtures. At the date of consummation of the Merger, property, plant and equipment is required to be measured at fair value, unless those assets are classified as held-for-sale on the closing date of the Merger. The acquired assets can include assets that are not intended to be used or sold, or that are intended to be used in a manner other than their highest and best use. Clywedog has only limited information at this time as to the specific nature, age, condition or location of the property, plant and equipment. All of these factors can cause differences between the fair value and net book value, and such differences could be material.
(iii) A preliminary fair value estimate of $1.6 million has been assigned to the right-of-use asset which consists of the laboratory and office facility in Germantown, Maryland, USA. Clywedog has limited information at this time as to the anticipated future use of the facility, and has therefore based the fair value assumptions on the original contractual terms of the facility lease. Any changes to the planned use of the facility can cause differences between the fair value and net book value, and such changes could be material.
(iv) A preliminary fair value estimate of $0.3 million has been assigned to deferred income which consists of income yet to be recognized from the Coalition for Epidemic Preparedness Innovations (“CEPI”) Funding Agreement, pursuant to which CEPI funds the development of VTP-500, the Barinthus Bio vaccine candidate against Middle East Respiratory Syndrome (“MERS”). Barinthus Bio has deprioritized this program however the CEPI Funding Agreement has not been terminated or novated, and Clywedog has limited information as to the expected outcome of the negotiations. Any developments can cause differences between the fair value and net book value, and such changes could be material.
4. Adjustments to the Unaudited Pro Forma Condensed Combined Balance Sheet as of June 30, 2026
(1) Derived from the unaudited Condensed Consolidated Balance Sheet of Clywedog Therapeutics Inc. as of June 30, 2026.
(2) Derived from the unaudited Condensed Consolidated Balance Sheet of Barinthus Biotherapeutics plc as of June 30, 2026.
(A) Represents the adjustment relating to the Self-Tender Offer that was completed on October 19, 2026 in which Topco accepted for purchase 920,605 shares of its common stock, par value $0.0001 per share that were properly tendered at a price of $6.6609 per share, for an aggregate purchase price of approximately $6.1 million.
| 10 |
(B) To reflect the payment of merger-related transaction costs incurred or expected to be incurred by Clywedog ($2.7 million) and Barinthus Bio ($8.5 million). These transaction costs will not recur in Topco’s results of operations after the Merger. The unpaid merger-related transaction costs of Barinthus Bio are reflected within the net assets acquired by Clywedog for purposes of the preliminary purchase price allocation. The merger-related transaction costs of Barinthus Bio not yet recognized in the historical financial statements as of June 30, 2026 are presented as a decrease to additional paid-in-capital.
(C) Represents the conversion of SAFE notes to preferred stock and immediately prior to the Combinations the conversion of the preferred stock to common stock.
(D) Represents the conversion of Clywedog Redeemable convertible preferred stock to common stock.
(E) Represents the elimination of the pre-acquisition equity of Barinthus Bio, including the elimination of Treasury Stock of $6.1 million that resulted from the Self-Tender Offer and the net decrease to additional paid-in capital to reflect the estimated net assets acquired from Barinthus Bio upon completion of the Merger as further discussed in in Note 3 above.
5. Adjustments to the Unaudited Pro Forma Condensed Combined Statements of Operations and Comprehensive Loss for the Six Months Ended June 30, 2026 and the Year Ended December 31, 2025
(3) Derived from the audited Consolidated Statement of Operations of Clywedog Therapeutics Inc. for the year ended December 31, 2025.
(4) Derived from the audited Consolidated Statement of Operations and Comprehensive Loss of Barinthus Biotherapeutics plc for the year ended December 31, 2025.
(5) Derived from the unaudited Condensed Consolidated Statement of Operations of Clywedog Therapeutics Inc. for the six months ended June 30, 2026.
(6) Derived from the unaudited Condensed Consolidated Statement of Operations and Comprehensive Loss of Barinthus Biotherapeutics plc for the six months ended June 30, 2026.
(AA) To reflect the elimination of $6.7 million of merger-related transaction costs incurred in the six months ended June 30, 2026 and the recognition of the related $2.7 million of Clywedog merger-related transaction costs in the year ended December 31, 2025 that are required to be expensed under U.S. GAAP, consisting of non-capitalizable professional service fees and other transaction-related costs. The unpaid transaction costs of Barinthus Bio are reflected within the net assets acquired by Clywedog for purposes of the preliminary purchase price allocation.
(BB) To reflect the elimination of the loss on change in fair value of the Clywedog SAFEs instruments upon conversion into Topco common stock.
(CC) Represents the gain on bargain purchase, which is non-taxable and non-recurring.
(DD) Represents additional post-combination share based compensation expense as a result of the replacement of Barinthus Bio stock options with Topco stock options. These amounts are based on the fair value, as of September 9, 2026, of Topco’s stock options which are issued as a replacement for the Barinthus stock options. Total additional post-combination share based compensation expense of $0.1 million is expected to be recognized over the remaining weighted-average service period of 1.2 years from the date of replacement.
(EE) The pro forma basic and diluted net loss per common share have been adjusted to reflect the pro forma net loss for six months ended June 30, 2026 and the year ended December 31, 2025. In addition, the number of shares used to calculate the pro forma basic and diluted net loss per common share has been adjusted to reflect the estimated total number of shares of common stock of the combined company that would be outstanding as of the date of the Closing as if they have been outstanding for the entirety of the period presented. For pro forma diluted net loss per share, the weighted-average number of shares of common stock is the same for pro forma basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive. For the six months ended June 30, 2026 and the year ended December 31, 2025, the pro forma weighted average common shares outstanding and pro forma net loss per common share, basic and diluted, were calculated as follows:
| Six Months Ended June 30, 2026 | Year Ended December 31, 2025 | |||||||
| Pro forma net loss attributable to shareholders | $ | (22,151 | ) | $ | (69,372 | ) | ||
| Weighted-average Clywedog shares outstanding, basic and diluted | 1,512,000 | 1,512,000 | ||||||
| Weighted-average Barinthus shares outstanding, basic and diluted | 40,848,893 | 40,527,218 | ||||||
| Pro forma Adjustment EE: | ||||||||
| Elimination of Barinthus historical weighted average shares outstanding | (40,848,893 | ) | (40,527,218 | ) | ||||
| Common stock issued to Barinthus common stockholders | 4,534,227 | 4,534,227 | ||||||
| Adjustments to Clywedog Common Stock for exchange ratio of 0.741416 | (390,980 | ) | (390,980 | ) | ||||
| Conversion of Clywedog Preferred Stock into common stock | 4,801,530 | 4,801,530 | ||||||
| Conversion of Clywedog SAFEs into common stock | 989,962 | 989,962 | ||||||
| Adjustment for Self Tender Offer | (920,605 | ) | (920,605 | ) | ||||
| Pro forma adjustment | (31,834,759 | ) | (31,513,084 | ) | ||||
| Pro forma weighted-average shares outstanding, basic and diluted | 10,526,134 | 10,526,134 | ||||||
| Pro forma net loss per share attributable to common shareholders, basic and diluted | $ | (2.10 | ) | $ | (6.59 | ) | ||
| 11 |